The receptors EphA-2 and IL-13Rα2 are notably overexpressed on tumor cells in these subtypes compared to normal epithelial cells, suggesting their potential as targets for CAR T-cell therapy [3,13,16,29,33,93,94,95,96,97]. The gene discussed is EPHA2; the disease is neoplasm.